West Nile Immune Globulin - OMRIX
Alternative Names: Omr-IgG-am™-WNIG; WNIGLatest Information Update: 07 Sep 2015
At a glance
- Originator OMRIX Biopharmaceuticals
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued West Nile virus infections
Most Recent Events
- 07 Sep 2015 Discontinued - Phase-II for West Nile virus infections in USA (IV)
- 16 Aug 2010 Phase-II clinical trials in West Nile virus infections in USA (IV)
- 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson